Comparative Pharmacology
Head-to-head clinical analysis: BILDYOS versus FARXIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BILDYOS versus FARXIGA.
BILDYOS vs FARXIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BILDYOS (pemigatinib) is a selective, potent, oral inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, and 3. It binds to the ATP-binding pocket of FGFR kinases, inhibiting autophosphorylation and downstream signaling, thereby reducing proliferation and survival of tumor cells with FGFR alterations.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose.
Adults: 20 mg orally once daily.
10 mg orally once daily, with or without food.
None Documented
None Documented
Approximately 24 hours at steady state; supports once-daily dosing.
Terminal elimination half-life 12-13 hours; supports once-daily dosing. Steady-state reached in 5 days.
Primarily biliary/fecal (unchanged drug and metabolites), approximately 90%; renal excretion accounts for less than 10% as unchanged drug and conjugates.
Renal (33% as parent, 66% as glucuronide conjugates in urine); fecal (1.5% as parent); biliary (minor).
Category C
Category C
SGLT2 Inhibitor/Biguanide Combination Antidiabetic
SGLT2 Inhibitor